The international retrospective study included 365 patients with newly diagnosed early-stage follicular lymphoma rigorously staged with PET-CT and bone marrow biopsy.
Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.
A new study evaluated whether the m7-FLIPI score in patients with follicular lymphoma treated with rituximab without chemotherapy can indicate prognosis.
Researchers conducted a study to determine if low levels of immune infiltration were associated with inferior outcomes among patients with follicular lymphoma.
While many patients with follicular lymphoma did well with this new regimen, the majority of those who did have disease progression had transformed disease.
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given rituximab to see how it affected progression-free survival.
Researchers from the Mayo Clinic in Rochester, Minn. examined the disease histology and outcomes of patients with diffuse large B-cell lymphoma and a concurrent lymphoma.
In this phase II GALEN study, researchers examined the effects of lenalidomide and obinutuzumab in patients with relapsed or refractory follicular lymphoma.
A new study looked at the rates of response and remission in patients with relapsed or refractory follicular lymphoma who underwent CD19-directed CAR-T cell therapy.
The CALGB 50904 trial tested the addition of bortezomib to ofatumumab and bendamustine in patients with previously untreated high-risk follicular lymphoma.